Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Medtronic AAA stent grafts

This article was originally published in The Gray Sheet

Executive Summary

Xcelerant delivery system earns CE mark for use with Talent abdominal aortic aneurysm stent graft. The system features improved catheter material and an integrated deployment handle to enhance trackability, aid kink resistance and decrease deployment force, resulting in reduced implant procedure times, Medtronic says. The company also launches "higher density" Resilient graft material for its U.S. AAA stent graft, the AneuRx. The material aims to "reduce porosity and improve durability," the firm explains July 14. Medtronic's AAA announcements follow controversy over an FDA-authored article about AneuRx safety data that was retracted from a peer-review journal after Medtronic threatened litigation over use of proprietary clinical data (1"The Gray Sheet" July 12, 2004, p. 29)...

You may also be interested in...

Medtronic Stands Behind Proprietary Nature Of AneuRx Clinical Data

AdvaMed's intent to craft a position on the release of proprietary data generated by manufacturers during clinical trials should gain momentum from recently publicized study data on Medtronic's AneuRx device

FDA Officials Cite Reasons For Denying Application Reviews Over Data Integrity Breaches

Officials from the US Food and Drug Administration cited their reasons for refusing to review new applications for companies with unresolved data integrity failures.

Vaccinex Sees Mixed Signals In Huntington’s Study

However, Vaccinex sees possible efficacy for SEMA4D inhibition in later-stage Huntington’s as well as Alzheimer’s disease. Pepinemab is also being studied with Keytruda in head-and-neck cancer.




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts